ANVISA Approval for CuraTeQ Biologics' Biosimilars Manufacturing Facility

CuraTeQ Biologics Private Limited, a wholly owned subsidiary of Aurobindo Pharma Limited, has received approval from ANVISA (Agência Nacional de Vigilância Sanitária), the National Health Surveillance Agency of Brazil, for its biosimilars manufacturing facility in Hyderabad.

The facility underwent a GMP inspection by ANVISA from May 11 to May 15, 2026, and the approval was granted following successful completion of the inspection for biological API and sterile products. The scope of the GMP inspection covered four biosimilar products and assessed the mammalian and microbial drug substance manufacturing facility, prefillable syringe and vial filling facility, packaging and labelling facility, QC testing and release laboratories.

CuraTeQ's drug substance and drug product GMP facility is already EMA (European Medicines Agency) and WHO certified and the ANVISA approval reaffirms CuraTeQ Biologics' commitment to global regulatory compliance and quality standards. The approval strengthens the Company's capability to supply biosimilar products to the Brazilian and broader Latin American markets.

Shares of Aurobindo Pharma Limited was last trading in BSE at Rs. 1560.55 as compared to the previous close of Rs. 1534.05. The total number of shares traded during the day was 42075 in over 2125 trades.

The stock hit an intraday high of Rs. 1573.90 and intraday low of 1537.60. The net turnover during the day was Rs. 65385744.00.

Source : Equity Bulls

Keywords

AurobindoPharma INE406A01037 Pharmaceuticals CuraTeQBiologics